Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
5AM Partners
San Francisco, California, USA
- Ownership
- Private
- Employees
- ~38
- Development stage
- Other
01
Overview
5AM Ventures' portfolio companies have over 90,000 patients enrolled across 450+ test sites in clinical trials. The firm has celebrated 20 FDA product approvals as of March 2023. Recent notable achievements include FDA approval of REZZAYO (rezafungin) for candidemia and invasive candidiasis.
- Therapeutic areas
- ImmunologyCardiovascularEndocrinologyNeurologyInfectious DiseasesPsychiatryPulmonologyRare DiseasesGastroenterologyRheumatologyOncology
- Modalities
- AntibodyAntibody-drug conjugateCAR-T cell therapyCell therapyGene therapyMonoclonal antibodymRNA-based drugsNK cell therapyRadiopharmaceuticalSmall molecule
- Industry
- Investors
Beyond the preview
Go deeper on 5AM Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5AM Partners.